On March 30, Cardiol Therapeutics Inc. (TSX: CRDL | OTCQX: CRTPF | FSE: CT9) announced the appointment of Dr Andrew Hamer as Cardiol’s new Chief Medical Officer. He will lead the research and development (R&D) of Cardiol’s clinical-stage products, along with overseeing the development of its novel therapeutic offerings.
What does Cardiol Therapeutics do?
Cardiol Therapeutics is a Canadian pharmaceutical company focused on producing medical cannabidiol (CBD) products along with a variety of therapies for heart diseases, including acute myocarditis and other causes of heart failure. Its lead product is CardiolRx™, which has FDA approval for a Phase II/III trial to test efficacy in improving outcomes for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). CardiolRx™ is a pharmaceutically produced CBD formulation.
Furthermore, Cardiol Therapeutics is developing a subcutaneous formulation of CardiolRx™ to deliver pharmaceutical CBD directly to inflamed areas of the heart commonly associated with heart failure.
Who is Dr Hamer?
With 30-years’ experience under his belt, Dr Hamer is well equipped to head up the R&D team. He’s worked in the global life sciences industry, medical affairs, and cardiology practice. This wide-ranging experience will serve him well in designing, implementing, and reporting the results of Cardiol’s exciting clinical programs.
Prior to arriving at Cardiol, Dr Hamer was employed as Executive Director, Global Development-Cardiometabolic at Amgen (NASDAQ:AMGN), a $146 billion biotech firm. In this role, which he held for five years, he led the Global Development group in developing Repatha®. This is an injectable prescription medicine used to treat high cholesterol levels. Repatha® generated revenues of almost $900 million last year.
Before Amgen, Dr Hamer worked at Capricor Therapeutics (NASDAQ:CAPR) for two years as VP of Medical Affairs. Here he handled the development of novel therapeutics, for heart disease and for the supervision of the clinical operations of the company, including clinical trial design and execution.
Formerly, he spent 19 years practicing cardiology and internal medicine in New Zealand. During this time he became Chief Cardiologist at Nelson Hospital, while simultaneously leading cardiac services nationally across New Zealand.
He has worked all over the world and co-authored many high-quality peer-reviewed scientific publications that reflect his wide-ranging experience as a clinical trialist.
Dr Hamer replaces Cardiol’s co-founder, Dr Eldon Smith, who is choosing to retire. However, Dr Smith will stay on as Chair of the Board of Directors and advisor to the Company.
Get our FREE IN-DEPTH REPORT to discover the wealth generating potential of investing in Cardiol Therapeutics!
Thrilled to be onboard
Dr Hamer is thrilled to be joining the Cardiol Therapeutics team:
“I am excited to be joining Cardiol Therapeutics and look forward to working with the outstanding leadership team in progressing the clinical development of the Company’s promising therapies. There are millions of patients worldwide suffering from heart disease, where inflammation is a critical underlying component, and they depend on the efforts of companies like Cardiol to develop new treatment options that are safe and effective. I am pleased to have the opportunity to play a leadership role in this important endeavour.”
Cardiol is equally happy to welcome him onboard. David Elsley, President and CEO of Cardiol Therapeutics comments:
“We are extremely pleased to have Andrew join our leadership team as we continue to advance our clinical development programs and promising basic research initiatives designed to explore additional therapeutic strategies to address inflammatory heart disease.”
Cardiol Therapeutics financials
In the past year, Cardiol Therapeutics has returned a compound annual growth rate (CAGR) of 50%. This equates to the return that investors that bought in a year ago have enjoyed.
The company has a market cap of CA$167 million. Its current share price is CA$4.51, which is 15% below its 52-week high and 127% above its 52-week low.
READ OUR SPECIAL REPORT – To Discover How Cardiol Therapeutics Is A Prime Stock For Shareholder Wealth Generation!
IMPORTANT NOTICE AND DISCLAIMER
PAID ADVERTISEMENT
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of forty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
INFORMATION
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
TERMS OF USE AND DISCLAIMER
By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.
INTELLECTUAL PROPERTY
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
AUTHORS: VALUETHEMARKETS
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.
